By otakuyassine3@gmail.com 
Claro Advisors LLC trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 14.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,186 shares of the medical research company’s stock after selling 726 shares during the period. Claro Advisors LLC’s holdings in Amgen were worth $1,091,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently bought and sold shares of the company. Parallel Advisors LLC grew its holdings in shares of Amgen by 0.8% during the 2nd quarter. Parallel Advisors LLC now owns 9,210 shares of the medical research company’s stock valued at $2,878,000 after acquiring an additional 70 shares in the last quarter. Envestnet Asset Management Inc. increased its position in Amgen by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 1,408,785 shares of the medical research company’s stock worth $440,175,000 after purchasing an additional 107,134 shares during the last quarter. Seven Mile Advisory raised its stake in shares of Amgen by 15.3% during the 2nd quarter. Seven Mile Advisory now owns 852 shares of the medical research company’s stock worth $266,000 after purchasing an additional 113 shares in the last quarter. Hanson & Doremus Investment Management lifted its holdings in shares of Amgen by 3.6% during the 2nd quarter. Hanson & Doremus Investment Management now owns 1,592 shares of the medical research company’s stock valued at $497,000 after buying an additional 55 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC increased its holdings in Amgen by 49.4% in the second quarter. Thompson Siegel & Walmsley LLC now owns 38,677 shares of the medical research company’s stock worth $12,085,000 after buying an additional 12,784 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several brokerages have recently commented on AMGN. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Piper Sandler cut their target price on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. William Blair reissued an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Wells Fargo & Company reduced their target price on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a report on Friday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $405.00 price target on shares of Amgen in a research report on Tuesday, October 22nd. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $314.91.
Check Out Our Latest Stock Analysis on AMGN
Amgen Price Performance
Shares of AMGN stock traded up $7.03 during mid-day trading on Monday, hitting $269.26. The company had a trading volume of 1,991,310 shares, compared to its average volume of 2,881,414. The company has a market capitalization of $144.74 billion, a P/E ratio of 34.48, a P/E/G ratio of 2.91 and a beta of 0.56. The stock’s 50 day moving average price is $279.10 and its 200-day moving average price is $308.66. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.
Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter in the previous year, the business posted $4.96 earnings per share. Amgen’s quarterly revenue was up 23.2% on a year-over-year basis. Equities research analysts forecast that Amgen Inc. will post 19.53 earnings per share for the current year.
Amgen Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.54%. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is presently 121.90%.
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Stories
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.